To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
Condition(s):Renal ImpairmentLast Updated:August 14, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Renal ImpairmentLast Updated:August 14, 2023Active, not recruiting
Condition(s):Renal ImpairmentLast Updated:April 5, 2022Completed
Condition(s):Severe Renal ImpairmentLast Updated:December 6, 2012Terminated
Condition(s):Renal ImpairmentLast Updated:March 8, 2023Completed
Condition(s):Infection, Human Immunodeficiency Virus; HIV InfectionsLast Updated:August 28, 2020Completed
Condition(s):HealthyLast Updated:November 29, 2021Completed
Condition(s):Renal ImpairmentLast Updated:March 12, 2020Completed
Condition(s):Renal Impaired; Gilteritinib; Normal Renal Function; Pharmacokinetics of ASP2215Last Updated:July 17, 2023Completed
Condition(s):Multiple Myeloma; Renal FailureLast Updated:May 6, 2023Completed
Condition(s):Renal ImpairmentLast Updated:February 8, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.